Is there a role for IGF-1 in the development of second primary cancers?

TY - JOUR

T1 - Is there a role for IGF-1 in the development of second primary cancers?

AU - Shanmugalingam, Thurkaa

AU - Bosco, Cecilia Teresita

AU - Ridley, Anne

AU - Van Hemelrijck, Mieke

PY - 2016/10/13

Y1 - 2016/10/13

N2 - Cancer survival rates are increasing, and as a result more cancer survivors are exposed to the risk of developing a second primary cancer (SPC). It has been hypothesised that one of the underlying mechanisms for this risk could be mediated by variations in insulin-like growth factor-1 (IGF-1). This review summarises the current epidemiological evidence to identify whether IGF-1 plays a role in the development of SPCs. IGF-1 is known to promote cancer development by inhibiting apoptosis and stimulating cell proliferation. Epidemiological studies have reported a positive association between circulating IGF-1 levels and various primary cancers, such as breast, colorectal and prostate cancer. The role of IGF-1 in increasing SPC risk has been explored less. Nonetheless, several experimental studies have observed a deregulation of the IGF-1 pathway, which may explain the association between IGF-1 and SPCs. Thus, measuring serum IGF-1 may serve as a useful marker in assessing the risk of SPCs, and therefore, more translational experimental and epidemiological studies are needed to further disentangle the role of IGF-1 in the development of specific SPCs.

AB - Cancer survival rates are increasing, and as a result more cancer survivors are exposed to the risk of developing a second primary cancer (SPC). It has been hypothesised that one of the underlying mechanisms for this risk could be mediated by variations in insulin-like growth factor-1 (IGF-1). This review summarises the current epidemiological evidence to identify whether IGF-1 plays a role in the development of SPCs. IGF-1 is known to promote cancer development by inhibiting apoptosis and stimulating cell proliferation. Epidemiological studies have reported a positive association between circulating IGF-1 levels and various primary cancers, such as breast, colorectal and prostate cancer. The role of IGF-1 in increasing SPC risk has been explored less. Nonetheless, several experimental studies have observed a deregulation of the IGF-1 pathway, which may explain the association between IGF-1 and SPCs. Thus, measuring serum IGF-1 may serve as a useful marker in assessing the risk of SPCs, and therefore, more translational experimental and epidemiological studies are needed to further disentangle the role of IGF-1 in the development of specific SPCs.

U2 - 10.1002/cam4.871

DO - 10.1002/cam4.871

M3 - Article

SN - 2045-7634

JO - Cancer Medicine

JF - Cancer Medicine

ER -